The US Food and Drug Administration (FDA) has cleared Intellia Therapeutics’ Investigational New Drug (IND) application for NTLA-2002 for the treatment of hereditary angioedema (HAE). Intellia is a clinical-stage genome editing company focused on developing potentially curative therapies using CRISPR-based technologies. The decision will enable the company to include the United States in the global […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!
